Objective: To determine calcitonin gene-related peptide (CGRP) levels outside migraine attacks in peripheral blood as a potential biomarker for chronic migraine (CM).
Migraine can be divided into 2 types of frequency: episodic migraine (EM) (fewer than 15 headache days per month) and chronic migraine (CM) (15 or more headache days per month). The International Headache Society (IHS) defines CM as 15 or more headache days per month for at least 3 months, with 8 or more days per month fulfilling migraine criteria, in the absence of medication overuse. 1 Migraine is considered to be a neurovascular disorder. Either changes in the modulating nociceptive inputs from the raphe and locus ceruleus nuclei in the brainstem or a cortical spreading depression phenomenon are thought to activate the trigeminovascular system. 2 During a migraine attack, trigeminal activation results in the release of vasoactive neuropeptides from its presynaptic nerve terminals, most especially calcitonin gene-related peptide (CGRP), which induces vasodilation and neurogenic inflammation in leptomeningeal and extracranial vessels giving rise to the typical throbbing migraine pain. [3] [4] [5] Although the source of pain persistence in CM is unknown, it is widely accepted that pain pathways become sensitized by repeated episodes of trigeminal activation. 6, 7 CGRP has an important role in migraine. 8, 9 CGRP is the only neurotransmitter reliably released in acute migraine attacks at present, IV CGRP causes headache only in patients with migraine, and CGRP antagonists are effective for the acute treatment of migraine. [9] [10] [11] [12] CGRP is a neuropeptide consisting of 37 amino acids predominantly expressed in the nervous system. Almost half of the cell bodies of human trigeminal ganglia contain CGRP. 8, 9 We determined interictal CGRP levels in peripheral blood in a series of women with CM as a potential biomarker for permanent trigeminovascular activation.
METHODS Study participants. Women older than 17 years attending our headache clinic at the University Hospital Central de Asturias who had been diagnosed by us as having CM according current IHS criteria were included in this study. 1 All patients fulfilling criteria for analgesic overuse had been detoxified at least once for a minimum of 2 months. As control groups, we recruited matched healthy women (medical students, residents, nurses, or physicians from our hospital) with subjective absence of headache and taking no medication and women also attending our clinic and meeting IHS diagnostic criteria for EM diagnosis. As an ancillary control group, we also studied patients with episodic cluster headache always outside a symptomatic period. All subjects underwent a general physical and neurologic examination. Without exception, migraine (chronic or episodic) had at least a normal neuroimaging study (brain MRI in 97 cases and brain CT with contrast in the remaining 49 cases). All episodic cluster headache cases had a normal brain MRI. Exclusion criteria were pregnant or breast-feeding women, excessive use of alcohol, and serious, active somatic, or psychiatric diseases.
Standard protocol approvals, registrations, and patient consents. The study was approved by the institutional ethic review board of our center, and all the participants gave written consent.
Procedures. Patients rested in supine position and blood samples
were obtained from the right antecubital vein between 9:30 AM and noon in a fasting condition. The blood was collected, allowed to clot, and serum was separated after centrifugation for 10 minutes at 2,000g. Aliquots were stored at 280°C until assayed. All samples were obtained in the absence of acute moderate-severe pain and having taken no symptomatic medication in the previous 24 hours. Fore ethical reasons, preventatives were not withdrawn.
Serum CGRP levels were determined using a commercial ELISA kit (USCN Life Science Inc., Hubei, China) strictly following manufacturer's instructions. Absorption levels were measured with a spectrophotometer from BioRad (Hercules, CA). The detection limit of the assay was ,4.3 pg/mL. Data analysis. CGRP levels and age (years) were described by mean 6 SDs. Absolute and relative frequencies were used for describing categorical variables. The classic nonparametric Mann-Whitney and the exact x 2 test were used to compare, respectively, the CGRP levels and the categorical variables by the different groups. The receiver operating characteristic (ROC) curve and the AUC (area under ROC curve) were obtained to measure the discrimination capacity (CM vs controls and CM vs EM) of the CGRP levels. The point associated with the Youden index was chosen as threshold point. Confidence band for the ROC curves and 95% confidence intervals (CIs) for both the AUC and the threshold were computed by 10,000 iterations of the bootstrap method. Finally, to check the diagnostic capacity of the proposed criteria, the leave-one-out method was performed.
RESULTS
We assessed plasma samples from 103 women with CM (mean age 43.1 6 11.7 years; range 18-65 years), 31 healthy women with no headache history (38.6 6 12.8 years; 21-61 years), 43 women with EM (44.4 6 11.6 years; 18-66 years), and 14 patients with episodic cluster headache (13 males, 45.4 6 7.9 years). By history, the average time in which patients had remained in a CM situation was 9.5 6 8.4 years (range 1-35 years). Comorbidities and treatment of women with CM enrolled in this study are illustrated in the table. CGRP levels were significantly higher in women with CM (74.90 6 28.29 pg/mL; range 29.0-157.72) as compared with control women (33.74 6 16.10 pg/ mL; range 15.53-70.75; p , 0.001), women with EM (46.37 6 15.21 pg/mL; range 17.55-94.73; p , 0.001 vs CM and p , 0.005 vs controls), and patients with episodic cluster headache (45.87 6 12.32 pg/mL) in an interictal period (figure 1). Both in the group of healthy controls and in the CM group, CGRP was not influenced by age in the range of our study (figure e-1 on the Neurology ® Web site at www.neurology.org). To evaluate the CGRP concentration as a potential marker for CM, the ROC curve and the AUC were measured. The Youden index was achieved for a CGRP concentration of 43.45 pg/mL (95% bootstrap CI: 30.91-49.06; figure 2A ) with an AUC of 0.912 (95% bootstrap CI: 0.8499-0.9640). For this threshold, 90.38% of the patients with CM and 80.64% of the controls would be correctly classified. The same discriminatory capacity was obtained by applying the leave-one-out method. Thereafter, the same methodology was applied to discriminate CM and EM. For a CGRP concentration of 58.22 pg/mL (95% bootstrap CI: 51.31-67.09), 69.23% of the patients with EM and 85.7% of the patients with CM were correctly classified (figure 2B).
A total of 46 women (44.66%) with CM had a history of migraine with aura attacks. There were only 4 women in this group experiencing aura at least once per month in the previous year. Within the sample of women with EM, 21 (48.84%) also had a history of migraine with aura attacks. CGRP levels were also significantly increased in the 46 women with CM and a history of migraine with aura attacks (81.29 6 27.11 pg/mL; 3 ).
In the group of women with CM, CGRP levels were not significantly different in patients meeting criteria for analgesic overuse (26 patients, 25.2%) vs those without analgesic overuse (72.70 6 30.46 pg/mL vs 74.93 6 27.68 pg/mL). CGRP levels were not statistically different in patients using triptans as symptomatic medication as compared with those who were not taking triptans. CGRP levels were not statistically different in patients taking preventatives in monotherapy vs polytherapy or in those taking topiramate vs those who were not using topiramate. In this group, CGRP levels did not change significantly in the presence/absence of a history of depression, fibromyalgia, and arterial hypertension. DISCUSSION The main finding of this work is that, as compared with healthy women without a history of headache, interictal CGRP levels were clearly elevated in peripheral blood in a large series of women with CM and, to a lesser degree, in women with EM. CGRP levels in patients with CM were shown to be significantly increased when compared with those of women with EM. Increased peripheral CGRP levels should be interpreted as a distant sign of activation of the trigeminovascular system; because its molecule is so large, CGRP cannot pass the blood-brain barrier. 8, 9 There have been only a few studies testing CGRP levels in migraine with contradictory results. While 2 works were able to detect a specific increased release of CGRP in the external jugular vein during the acute migraine attack, 4, 13 which was reversed by the administration of triptans, another study found no CGRP increase during migraine attacks also in jugular venous samples. 14 In this negative study, the researcher visited patients at their home or workplace and the time between sampling and centrifugation has been considered as too prolonged, which, considering the rather short half-life of CGRP, would predict little neuropeptide left in the sample. 15 Because of the obvious difficulties in obtaining jugular vein samples, several groups have already measured CGRP levels in peripheral blood in small series of patients with migraine. CGRP levels have been found consistently elevated during migraine attacks as compared with controls in cubital vein samples. 16, 17 Interestingly, an increase in peripheral CGRP levels in interictal, headache-free periods has been detected in patients with EM recruited from specialized headache clinics. 18, 19 Similar results have been obtained measuring salivary levels of CGRP in migraine subjects between attacks. 20, 21 There are no data on CGRP blood levels in patients with CM. Higher levels were found in the CSF of patients with CM with and without medication overuse as compared with controls in one study. 22 There was no difference in interictal plasma levels of CGRP in patients with chronic tension-type headache and healthy control subjects in one study, but an exploratory analysis showed that 8 patients whose usual headache quality was throbbing, who would probably have been diagnosed according to the 2006 criteria as having CM, had significantly higher antecubital CGRP levels than control subjects. 23 Our results show for the first time increased CGRP levels in CM outside migraine attacks and in the absence of symptomatic medication for at least 24 hours. Although we are aware that the fact that, for ethical reasons, most of our patients with migraine were receiving daily preventatives could be considered as a limitation of this study, it is also true that this could make our results even more relevant because these drugs could reduce to some degree trigeminovascular system activation and as a consequence decrease CGRP release. At least theoretically, peripheral CGRP levels could also serve to objectively contribute to monitor migraine status and response to preventive treatments. As an example of this, 14 of the 43 women in a current EM situation had met in the past CM criteria, which could be reversed with preventive treatments. Mean CGRP levels in this subset of patients was 39.7 pg/mL, that is, in the range of EM and far from that of CM.
CGRP levels were significantly higher in women with CM having a history of migraine with aura attacks vs those who had never experienced an aura. A similar tendency was suggested in 2 of the studies examining Influence of aura on CGRP levels
Box plot for the calcitonin gene-related peptide (CGRP) levels in chronic migraine (CM) and episodic migraine (EM) (in gray) by aura vs no aura.
CGRP levels in patients with migraine coming to specialized headache clinics. [16] [17] [18] [19] There are several potential explanations for this increased level of CGRP in women with CM and a history of aura. First, it would support the proposal that the pathophysiologic mechanism of the aura, the cortical spreading depression phenomenon, is enough to activate sensory nerve terminals around pial blood vessels. 24 Second, it is also possible that aura develops in general attacks with more severe pain. 25 In contrast to these 2 explanations, although a history of aura was rather common in our CM series, there were only 4 patients experiencing at least 1 aura per month. Finally, it is possible that the reason for our results could be that aura works as an ideal marker for a sure migraine diagnosis.
A variety of clinical comorbidities did not correlate, even numerically, with a change in CGRP levels. Interestingly, CGRP levels were remarkably similar in CM women with and without analgesic overuse. Even considering that all of the women in our study with CM meeting overuse criteria had tried formal withdrawal of symptomatic medications at least once and for 2 months without success, these results are a further proof that both subtypes of CM, with and without analgesic overuse, would share the same pathophysiologic substrate.
We still do not have a good understanding of the pathophysiology of CM or of the exact mechanisms that lead to transformation from EM to CM. It is well established, however, that activation of the trigeminovascular system has a crucial role and leads to afferent and efferent release of neuropeptides, especially CGRP. This facilitates a peripheral inflammatory and vasodilating response and causes activation of second-order neurons involved in pain transmission. In most vessels, CGRP causes endothelium-and nitric oxideindependent vasodilation through a direct action on the smooth muscle cells mediated both by cyclic adenosine monophosphate and activation of adenosine triphosphate-dependent K 1 channels. 26, 27 Persistent release of CGRP is thought to induce sensitization of central trigeminal neurons triggering a signaling pathway mediated by brain-derived neurotrophic factor leading to increased expression of a gene encoding the P2X receptors. 28, 29 These peptidergic central neurons in dorsal horn and trigeminal nucleus caudalis use L-glutamate as their primary neurotransmitter. CGRP, acting via a unique receptor complex, increases neurotransmitter release at these levels, which would lead to central sensitization underlying chronic pain states such as CM. 5, 6 What could be the clinical utility of our results? Peripheral CGRP levels outside migraine attacks and in the absence of symptomatic medication seem to be a reliable biomarker for CM allowing us to monitor patient status and perhaps response to preventive treatment, which could be of great help, for instance, for a more objective follow-up of patients included in clinical trials. Is this interictal increase in CGRP levels specific for CM vs other headaches? CGRP levels have been shown to be increased during attacks in patients with cluster headaches, 30 but there are no published data showing a role for CGRP as a biomarker for these headaches in headache-free periods. Our preliminary analysis in 14 patients with episodic cluster headache (13 males) shows that interictal CGRP levels are in the range of EM and do not reach those seen for CM. 30 CGRP levels have already been found to be similar to those of controls without headache in 2 important differential diagnoses for CM: chronic tension-type headache, 23 and cervicogenic headache. 31 This study has some limitations. First, our results come from a selected headache clinic population with still a limited number of patients and healthy controls. Second, the actual value of CGRP levels for monitoring the status of patients with migraine would only be possible with longitudinal data. Finally, to demonstrate true specificity, CGRP levels should be studied in entities such as new daily persistent headache, hemicrania continua, and in several secondary headaches that can mimic a CM phenotype. Keeping these limitations in mind, it seems that interictal CGRP levels are somewhat specific and sensitive for CM in the context of a patient with a daily or almost daily headaches and a history of migraine, which could be of great help on sharpening the diagnosis of the primary headache disorders and supports the proposal for a key role of CGRP of sensitization of pain circuits leading to CM. 9 
